Literature DB >> 20339926

B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells.

Shaoli Deng1, Tao Yuan, Xiaoxing Cheng, Rui Jian, Jing Jiang.   

Abstract

B-lymphocyte-induced maturation protein1(Blimp-1) and B-cell maturation antigen (BCMA) are essential factors in the development and survival of plasma cells. However, whether Blimp-1 could regulate the expression of BCMA is unknown. We found that the BCMA promoter region did not have typical "TATA" and "CAAT" box, but contained several potential binding sites of transcription factors, including the consensus sequences for Blimp-1, located in the "-31 to -21" and "-46 to -36" from the potential transcription initiation site of the mouse BCMA gene, respectively. Furthermore, induction of Blimp-1 over-expression significantly up-regulated the expression of BCMA and increased the BCMA promoter activity in mouse J558L plasma cells. In parallel, knockdown of Blimp-1 expression by the Blimp-1-specific shRNA significantly reduced the BCMA mRNA transcription and protein expression in J558L cells in vitro. Substitution mutation of the "-38 to -42" sequence, but not the "-23 to -27", in the BCMA promoter abolished the regulatory effect of Blimp-1 on the expression of BCMA. Importantly, Blimp-1 bound to the "GAAAC", but not its mutant "GATTC", contained BCMA promoter, as determined by competitive electrophoretic mobility shift assay (EMSA). Therefore, our data clearly suggest that Blimp-s a positive regulator of the expression of BCMA gene in mouse plasma cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339926     DOI: 10.1007/s11033-010-0028-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  30 in total

1.  Characterization of DNA-binding proteins using multiplexed competitor EMSA.

Authors:  Andrew J P Smith; Steve E Humphries
Journal:  J Mol Biol       Date:  2008-11-27       Impact factor: 5.469

Review 2.  Immune therapies of autoimmune diseases: are we approaching a real cure?

Authors:  Lucienne Chatenoud
Journal:  Curr Opin Immunol       Date:  2006-09-29       Impact factor: 7.486

3.  TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.

Authors:  A Hatzoglou; J Roussel; M F Bourgeade; E Rogier; C Madry; J Inoue; O Devergne; A Tsapis
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

4.  Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma.

Authors:  Nancy D Borson; Martha Q Lacy; Peter J Wettstein
Journal:  Blood       Date:  2002-12-15       Impact factor: 22.113

5.  B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites.

Authors:  Tracy C Kuo; Kathryn L Calame
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Structure of the human Bim gene and its transcriptional regulation in Baf-3, interleukin-3-dependent hematopoietic cells.

Authors:  Hirotaka Matsui; Tetsuharu Shinjyo; Toshiya Inaba
Journal:  Mol Biol Rep       Date:  2005-06       Impact factor: 2.316

7.  Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

Authors:  Anne J Novak; Jaime R Darce; Bonnie K Arendt; Brandon Harder; Kathy Henderson; Wayne Kindsvogel; Jane A Gross; Philip R Greipp; Diane F Jelinek
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

Review 8.  Tumor necrosis factor family ligand-receptor binding.

Authors:  Gongyi Zhang
Journal:  Curr Opin Struct Biol       Date:  2004-04       Impact factor: 6.809

9.  Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.

Authors:  Kuo-I Lin; Cristina Angelin-Duclos; Tracy C Kuo; Kathryn Calame
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

10.  Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow.

Authors:  Miriam Shapiro-Shelef; Kuo-I Lin; David Savitsky; Jerry Liao; Kathryn Calame
Journal:  J Exp Med       Date:  2005-11-28       Impact factor: 14.307

View more
  10 in total

Review 1.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

2.  A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

Authors:  Shaun M Flint; Adele Gibson; Geoff Lucas; Raghava Nandigam; Louise Taylor; Drew Provan; Adrian C Newland; Caroline O Savage; Robert B Henderson
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

3.  CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif.

Authors:  Cheryl H Rozanski; Adam Utley; Louise M Carlson; Matthew R Farren; Megan Murray; Lisa M Russell; Jayakumar R Nair; ZhengYu Yang; William Brady; Lee Ann Garrett-Sinha; Stephen P Schoenberger; Jonathan M Green; Lawrence H Boise; Kelvin P Lee
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

4.  A modular design for minor groove binding and recognition of mixed base pair sequences of DNA.

Authors:  Pu Guo; Ananya Paul; Arvind Kumar; Narinder K Harika; Siming Wang; Abdelbasset A Farahat; David W Boykin; W David Wilson
Journal:  Chem Commun (Camb)       Date:  2017-09-07       Impact factor: 6.222

5.  Inhibition of B lymphocyte-induced maturation protein-1 reduces the production of autoantibody and alleviates symptoms of systemic lupus erythematosus.

Authors:  Jie Luo; Xiaochang Niu; Mingxu Zhang; Kejun Zhang; Ming Chen; Shaoli Deng
Journal:  Autoimmunity       Date:  2014-10-27       Impact factor: 2.815

Review 6.  The Maintenance of Memory Plasma Cells.

Authors:  Laleh Khodadadi; Qingyu Cheng; Andreas Radbruch; Falk Hiepe
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 7.  BCMA-targeted immunotherapy for multiple myeloma.

Authors:  Bo Yu; Tianbo Jiang; Delong Liu
Journal:  J Hematol Oncol       Date:  2020-09-17       Impact factor: 17.388

Review 8.  Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.

Authors:  Shih-Feng Cho; Lijie Xing; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 9.  B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.

Authors:  Shirin Teymouri Nobari; Jafar Nouri Nojadeh; Mehdi Talebi
Journal:  J Transl Med       Date:  2022-02-10       Impact factor: 5.531

Review 10.  Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Authors:  Shih-Feng Cho; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.